BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MeiraGTx (MGTX)MeiraGTxEarnings

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to

Related news

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRQRProQR Therapeutics2026-08-13 11:00 EST

ProQR Announces Second Quarter 2026 Operating and Financial Results

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

MNPRMonopar2026-08-12 13:30 EST

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

PHVSPharvaris2026-08-12 10:50 EST

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

SANASana Biotechnology2026-08-10 20:05 EST

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

View all latest news

MeiraGTx

Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...

Recent company news

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Stock data

Close
13.77 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States